- Actinium Pharmaceuticals Inc ATNM announced positive topline results from the pivotal Phase 3 trial for its lead product candidate Iomab-B, a first-in-class targeted radiotherapy.
- The SIERRA trial was conducted in patients 55 or older with active disease (relapsed or refractory Acute Myeloid Leukemia).
- Related: With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium.
- The SIERRA trial compared Iomab-B as a conditioning (preparing) regimen before a Bone Marrow Transplant (BMT) versus a control arm which allowed all current means of conventional care with the intent to transplant these patients.
- The SIERRA trial met its primary endpoint of durable complete remission (dCR) of 6 months post initial remission after a BMT in the Iomab-B arm compared to the conventional care arm demonstrating statistical significance.
- "We look forward to sharing additional clinical data from the SIERRA trial by year-end," commented Sandesh Seth, Actinium's Chairman & CEO.
- In previously highlighted data, a 100% BMT and engraftment rate for patients receiving a therapeutic dose of Iomab-B was observed compared to 18% of patients receiving a physician's choice of salvage therapy on the control arm.
- Price Action: ATNM shares are up 24.82% at $12.15 on the last check Monday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.